Stage analysis of gastric cancer: a bioinformatic approach
Gastroenterology and Hepatology from Bed to Bench,
,
2 March 2026
,
Page 1-8 (e10)
https://doi.org/10.22037/ghfbb.v19i01.3260
Abstract
Aim: Analysis of stage transition in gastric cancer is the aim of this project.
Background: Gastric cancer, as a lethal digestive cancer, is classified based on tumor, node, and metastasis. Early detection of gastric cancer facilitates cancer management and treatment.
Methods: Data on gene expression changes at different stages of gastric cancer are extracted from the Gene Expression Omnibus (GEO) database and evaluated using the GEO2R program to identify significantly differentially expressed genes (DEGs). The queried DEGs were enriched via Gene Ontology to explore dysregulated pathways. The crucial DEGs were identified via directed protein-protein interaction (PPI) analysis.
Results: Analyses revealed that stage IA → stage IIA and stage IB → stage IIB transitions in gastric cancer are accompanied by considerable numbers of significant DEGs. MYC, “Nitric oxide metabolism in cystic fibrosis”, and “Hepatitis C and hepatocellular carcinoma” are the critical dysregulate gene and pathways in the stage IB → stage IIB transition. ACTG2, MYH11, CDKN2A, MS4A2, and FCER1A were pointed out as the critical genes in the IA → IIA stage transition.
Conclusion: In conclusion, inhibition of MYC was introduced as a crucial point in preventing the stage IB → stage IIB transition, and “Smooth muscle damage” was identified as a key process in stage IA → stage IIA transition. Experimental validation is recommended to find the applicable findings.
- Gastric cancer, staging, gene, pathway, network analysis
How to Cite
References
1. Chen Z-d, Zhang P-f, Xi H-q, Wei B, Chen L, Tang Y. Recent advances in the diagnosis, staging, treatment, and prognosis of advanced gastric cancer: a literature review. Front Med 2021;8:744839.
2. Wittekind C. The development of the TNM classification of gastric cancer. Pathol Int 2015;65:399-403.
3. Zhu Z, Gong Y, Xu H. Clinical and pathological staging of gastric cancer: current perspectives and implications. Eur J Surg Oncol 2020;46:e14-e9.
4. Kwon SJ. Evaluation of the 7th UICC TNM staging system of gastric cancer. J Gastric Cancer 2011;11:78-85.
5. Crosby D, Bhatia S, Brindle KM, Coussens LM, Dive C, Emberton M, et al. Early detection of cancer. Science 2022;375:eaay9040.
6. Fitzgerald RC, Antoniou AC, Fruk L, Rosenfeld N. The future of early cancer detection. Nat Med 2022;28:666-77.
7. Abidalkareem A, Ibrahim AK, Abd M, Rehman O, Zhuang H. Identification of gene expression in different stages of breast cancer with machine learning. Cancers 2024;16:1864.
8. Alharbi F, Vakanski A. Machine learning methods for cancer classification using gene expression data: A review. Bioengineering 2023;10:173.
9. Hosseinpour Z, Rezaei-Tavirani M, Akbari M-E, Farahani M. Developing a gene expression classifier for breast cancer diagnosis. Med Biol Eng Comput 2025:1-17.
10. Tavirani MR, Okhovatian F, Nejad MR, Arjmand B, Razzaghi Z. Predicting radioresistant biomarkers in nasopharyngeal carcinoma patients via protein-protein interaction network analysis. J Lasers Med Sci 2021;12:e76.
11. Tavirani MR, Tavirani SR. Gene screening of astrocytoma grade III relative to grade II via network analysis: a new molecular insight. Int J Cancer Manag 2018;11:e83201.
12. Rhodin KE, Raman V, Eckhoff A, Liu A, Creasy J, Nussbaum DP, et al. Patterns and impact of fragmented care in stage II and III gastric cancer. Ann Surg Oncol 2022;29:5422.
13. Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet 2020;396:635-48.
14. Duffy MJ, O'Grady S, Tang M, Crown J. MYC as a target for cancer treatment. Cancer Treat Rev 2021;94:102154.
15. Madden SK, de Araujo AD, Gerhardt M, Fairlie DP, Mason JM. Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc. Mol Cancer 2021;20:3.
16. Wang C, Zhang J, Yin J, Gan Y, Xu S, Gu Y, et al. Alternative approaches to target Myc for cancer treatment. Signal Transduct Target Ther 2021;6:117.
17. Mazurek M, Rola R. The implications of nitric oxide metabolism in the treatment of glial tumors. Neurochem Int 2021;150:105172.
18. Ene CD, Tampa M, Georgescu SR, Matei C, Leulescu IMT, Dogaru CI, et al. Disturbances in nitric oxide cycle and related molecular pathways in clear cell renal cell carcinoma. Cancers 2023;15:5797.
19. Kanda T, Yokosuka O, Omata M. Hepatitis C virus and hepatocellular carcinoma. Biology 2013;2:304-16.
20. Deng C, Li Z-x, Xie C-j, Zhang Q-l, Hu B-s, Wang M-d, et al. Pan-cancer analysis of CDKN2A alterations identifies a subset of gastric cancer with a cold tumor immune microenvironment. Hum Genomics 2024;18:55.
21. Shuai Y, Wenwen Z, Jingwen X, Qingqing F, Wenfei Z, Lili Z, et al. an investigation into the influence of actg2 on gastric cancer prognosis and cellular biological behaviors. Res Sq 2025. DOI: 10.21203/rs.3.rs-6582968/v1.
22. He F, Ding H, Zhou Y, Wang Y, Xie J, Yang S, et al. Depiction of aging-based molecular phenotypes with diverse clinical prognosis and immunological features in gastric cancer. Front Med 2022;8:792740.
23. Gélébart P, Kovács T, Brouland J-P, van Gorp R, Grossmann J, Rivard N, et al. Expression of endomembrane calcium pumps in colon and gastric cancer cells: induction of SERCA3 expression during differentiation. J Biol Chem 2002;277:26310-20.
- Abstract Viewed: 314 times
- PDF Downloaded: 211 times